Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease

Anupriya Agarwal, Thomas G.P. Bumm, Amie S. Corbin, Thomas O'Hare, Marc Loriaux, Jonathan Van Dyke, Stephanie G. Willis, Jutta Deininger, Keiichi I. Nakayama, Brian J. Druker, Michael W. Deininger

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

BCR-ABL is proposed to impair cell-cycle control by disabling p27, a tumor suppressor that inhibits cyclin-dependent kinases. We show that in cell lines p27 expression is inversely correlated with expression of SKP2, the F-box protein of SCF SKP2 (SKP1/Cul1/F-box), the E3 ubiquitin ligase that promotes proteasomal degradation of p27. Inhibition of BCR-ABL kinase causes G 1 arrest, downregulation of SKP2, and accumulation of p27. Ectopic expression of wild-type SKP2, but not a mutant unable to recognize p27, partially rescues cell-cycle progression. A similar regulation pattern is seen in cell lines transformed by FLT3-ITD, JAK2 V617F, and TEL-PDGFRβ, suggesting that the SKP2/p27 conduit may be a universal target for leukemogenic tyrosine kinases. Mice that received transplants of BCR-ABL-infected SKP2 -/- marrow developed a myeloproliferative syndrome but survival was significantly prolonged compared with recipients of BCR-ABL-expressing SKP2 +/+ marrow. SKP2 -/- leukemic cells demonstrated higher levels of nuclear p27 than SKP2 +/+ counterparts, suggesting that the attenuation of leukemogenesis depends on increased p27 expression. Our data identify SKP2 as a crucial mediator of BCR-ABL-induced leukemogenesis and provide the first in vivo evidence that SKP2 promotes oncogenesis. Hence, stabilization of p27 by inhibiting its recognition by SCF SKP2 may be therapeutically useful.

Original languageEnglish
Pages (from-to)1960-1970
Number of pages11
JournalBlood
Volume112
Issue number5
DOIs
Publication statusPublished - Sep 1 2008

Fingerprint

S-Phase Kinase-Associated Proteins
Bone Marrow
Cells
F-Box Proteins
Transformed Cell Line
Ubiquitin-Protein Ligases
Cyclin-Dependent Kinases
Cell Cycle Checkpoints
Protein-Tyrosine Kinases
Cell Cycle
Carcinogenesis
Phosphotransferases
Down-Regulation
Transplants
Cell Line
Tumors
Neoplasms
Stabilization
Degradation

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Agarwal, A., Bumm, T. G. P., Corbin, A. S., O'Hare, T., Loriaux, M., Van Dyke, J., ... Deininger, M. W. (2008). Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood, 112(5), 1960-1970. https://doi.org/10.1182/blood-2007-09-113860

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. / Agarwal, Anupriya; Bumm, Thomas G.P.; Corbin, Amie S.; O'Hare, Thomas; Loriaux, Marc; Van Dyke, Jonathan; Willis, Stephanie G.; Deininger, Jutta; Nakayama, Keiichi I.; Druker, Brian J.; Deininger, Michael W.

In: Blood, Vol. 112, No. 5, 01.09.2008, p. 1960-1970.

Research output: Contribution to journalArticle

Agarwal, A, Bumm, TGP, Corbin, AS, O'Hare, T, Loriaux, M, Van Dyke, J, Willis, SG, Deininger, J, Nakayama, KI, Druker, BJ & Deininger, MW 2008, 'Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease', Blood, vol. 112, no. 5, pp. 1960-1970. https://doi.org/10.1182/blood-2007-09-113860
Agarwal A, Bumm TGP, Corbin AS, O'Hare T, Loriaux M, Van Dyke J et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood. 2008 Sep 1;112(5):1960-1970. https://doi.org/10.1182/blood-2007-09-113860
Agarwal, Anupriya ; Bumm, Thomas G.P. ; Corbin, Amie S. ; O'Hare, Thomas ; Loriaux, Marc ; Van Dyke, Jonathan ; Willis, Stephanie G. ; Deininger, Jutta ; Nakayama, Keiichi I. ; Druker, Brian J. ; Deininger, Michael W. / Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. In: Blood. 2008 ; Vol. 112, No. 5. pp. 1960-1970.
@article{2cffda231a7148508e3593b8bab88fc2,
title = "Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease",
abstract = "BCR-ABL is proposed to impair cell-cycle control by disabling p27, a tumor suppressor that inhibits cyclin-dependent kinases. We show that in cell lines p27 expression is inversely correlated with expression of SKP2, the F-box protein of SCF SKP2 (SKP1/Cul1/F-box), the E3 ubiquitin ligase that promotes proteasomal degradation of p27. Inhibition of BCR-ABL kinase causes G 1 arrest, downregulation of SKP2, and accumulation of p27. Ectopic expression of wild-type SKP2, but not a mutant unable to recognize p27, partially rescues cell-cycle progression. A similar regulation pattern is seen in cell lines transformed by FLT3-ITD, JAK2 V617F, and TEL-PDGFRβ, suggesting that the SKP2/p27 conduit may be a universal target for leukemogenic tyrosine kinases. Mice that received transplants of BCR-ABL-infected SKP2 -/- marrow developed a myeloproliferative syndrome but survival was significantly prolonged compared with recipients of BCR-ABL-expressing SKP2 +/+ marrow. SKP2 -/- leukemic cells demonstrated higher levels of nuclear p27 than SKP2 +/+ counterparts, suggesting that the attenuation of leukemogenesis depends on increased p27 expression. Our data identify SKP2 as a crucial mediator of BCR-ABL-induced leukemogenesis and provide the first in vivo evidence that SKP2 promotes oncogenesis. Hence, stabilization of p27 by inhibiting its recognition by SCF SKP2 may be therapeutically useful.",
author = "Anupriya Agarwal and Bumm, {Thomas G.P.} and Corbin, {Amie S.} and Thomas O'Hare and Marc Loriaux and {Van Dyke}, Jonathan and Willis, {Stephanie G.} and Jutta Deininger and Nakayama, {Keiichi I.} and Druker, {Brian J.} and Deininger, {Michael W.}",
year = "2008",
month = "9",
day = "1",
doi = "10.1182/blood-2007-09-113860",
language = "English",
volume = "112",
pages = "1960--1970",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease

AU - Agarwal, Anupriya

AU - Bumm, Thomas G.P.

AU - Corbin, Amie S.

AU - O'Hare, Thomas

AU - Loriaux, Marc

AU - Van Dyke, Jonathan

AU - Willis, Stephanie G.

AU - Deininger, Jutta

AU - Nakayama, Keiichi I.

AU - Druker, Brian J.

AU - Deininger, Michael W.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - BCR-ABL is proposed to impair cell-cycle control by disabling p27, a tumor suppressor that inhibits cyclin-dependent kinases. We show that in cell lines p27 expression is inversely correlated with expression of SKP2, the F-box protein of SCF SKP2 (SKP1/Cul1/F-box), the E3 ubiquitin ligase that promotes proteasomal degradation of p27. Inhibition of BCR-ABL kinase causes G 1 arrest, downregulation of SKP2, and accumulation of p27. Ectopic expression of wild-type SKP2, but not a mutant unable to recognize p27, partially rescues cell-cycle progression. A similar regulation pattern is seen in cell lines transformed by FLT3-ITD, JAK2 V617F, and TEL-PDGFRβ, suggesting that the SKP2/p27 conduit may be a universal target for leukemogenic tyrosine kinases. Mice that received transplants of BCR-ABL-infected SKP2 -/- marrow developed a myeloproliferative syndrome but survival was significantly prolonged compared with recipients of BCR-ABL-expressing SKP2 +/+ marrow. SKP2 -/- leukemic cells demonstrated higher levels of nuclear p27 than SKP2 +/+ counterparts, suggesting that the attenuation of leukemogenesis depends on increased p27 expression. Our data identify SKP2 as a crucial mediator of BCR-ABL-induced leukemogenesis and provide the first in vivo evidence that SKP2 promotes oncogenesis. Hence, stabilization of p27 by inhibiting its recognition by SCF SKP2 may be therapeutically useful.

AB - BCR-ABL is proposed to impair cell-cycle control by disabling p27, a tumor suppressor that inhibits cyclin-dependent kinases. We show that in cell lines p27 expression is inversely correlated with expression of SKP2, the F-box protein of SCF SKP2 (SKP1/Cul1/F-box), the E3 ubiquitin ligase that promotes proteasomal degradation of p27. Inhibition of BCR-ABL kinase causes G 1 arrest, downregulation of SKP2, and accumulation of p27. Ectopic expression of wild-type SKP2, but not a mutant unable to recognize p27, partially rescues cell-cycle progression. A similar regulation pattern is seen in cell lines transformed by FLT3-ITD, JAK2 V617F, and TEL-PDGFRβ, suggesting that the SKP2/p27 conduit may be a universal target for leukemogenic tyrosine kinases. Mice that received transplants of BCR-ABL-infected SKP2 -/- marrow developed a myeloproliferative syndrome but survival was significantly prolonged compared with recipients of BCR-ABL-expressing SKP2 +/+ marrow. SKP2 -/- leukemic cells demonstrated higher levels of nuclear p27 than SKP2 +/+ counterparts, suggesting that the attenuation of leukemogenesis depends on increased p27 expression. Our data identify SKP2 as a crucial mediator of BCR-ABL-induced leukemogenesis and provide the first in vivo evidence that SKP2 promotes oncogenesis. Hence, stabilization of p27 by inhibiting its recognition by SCF SKP2 may be therapeutically useful.

UR - http://www.scopus.com/inward/record.url?scp=52649104330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649104330&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-09-113860

DO - 10.1182/blood-2007-09-113860

M3 - Article

C2 - 18559973

AN - SCOPUS:52649104330

VL - 112

SP - 1960

EP - 1970

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -